Cargando…

Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.

The effects of interferon-alpha (IFN) plus tamoxifen (TMX) in the treatment of advanced breast cancer were assessed. Changes of in vivo biologic determinants including hormone receptors, P24 protein, Ki-67 and growth factor expression were evaluated. Seven patients with advanced, heavily pretreated,...

Descripción completa

Detalles Bibliográficos
Autores principales: Seymour, L., Bezwoda, W. R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968584/
https://www.ncbi.nlm.nih.gov/pubmed/8347490
_version_ 1782134772357660672
author Seymour, L.
Bezwoda, W. R.
author_facet Seymour, L.
Bezwoda, W. R.
author_sort Seymour, L.
collection PubMed
description The effects of interferon-alpha (IFN) plus tamoxifen (TMX) in the treatment of advanced breast cancer were assessed. Changes of in vivo biologic determinants including hormone receptors, P24 protein, Ki-67 and growth factor expression were evaluated. Seven patients with advanced, heavily pretreated, breast cancer with accessible disease, underwent biopsy prior to and after sequential treatment with IFN and IFN plus TMX. Clinically 4/7 patients responded to treatment with one complete and three partial remissions. Apart from the favourable response rate the sequential in vivo changes in expression of tumour variables were of considerable interest. IFN treatment consistently increased the expression of the estrogen receptor (ER) and of the estrogen regulated protein P24 while decreasing the expression of the proliferation associated antigen Ki-67. Addition of TMX on the other hand resulted in a reduction of ER expression to pre-IFN levels and a rise in progesterone receptor (PR) expression. When the effect of either IFN or IFN plus TMX on the expression of two growth factors was assessed they were found to be somewhat variable. While PDGF expression tended to be suppressed, there was no clinical correlation with response to therapy. TGF beta expression was found in all patients prior to treatment and while all non-responders showed reduction of TGF beta following treatment, the alterations were variable amongst responders (including two patients with increased expression, one with no change, and one with decreased expression). It is concluded that both IFN and TMX exert multiple effects on the expression of tumour biologic variables and that while the study confirmed some of the predictions from in vitro models, the in vivo effect are more complex than has been appreciated from the models. From the clinical point of view, it might be expected that treatment which enhances the expression of ER in tumours should have a positive effect on the response to TMX.
format Text
id pubmed-1968584
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19685842009-09-10 Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Seymour, L. Bezwoda, W. R. Br J Cancer Research Article The effects of interferon-alpha (IFN) plus tamoxifen (TMX) in the treatment of advanced breast cancer were assessed. Changes of in vivo biologic determinants including hormone receptors, P24 protein, Ki-67 and growth factor expression were evaluated. Seven patients with advanced, heavily pretreated, breast cancer with accessible disease, underwent biopsy prior to and after sequential treatment with IFN and IFN plus TMX. Clinically 4/7 patients responded to treatment with one complete and three partial remissions. Apart from the favourable response rate the sequential in vivo changes in expression of tumour variables were of considerable interest. IFN treatment consistently increased the expression of the estrogen receptor (ER) and of the estrogen regulated protein P24 while decreasing the expression of the proliferation associated antigen Ki-67. Addition of TMX on the other hand resulted in a reduction of ER expression to pre-IFN levels and a rise in progesterone receptor (PR) expression. When the effect of either IFN or IFN plus TMX on the expression of two growth factors was assessed they were found to be somewhat variable. While PDGF expression tended to be suppressed, there was no clinical correlation with response to therapy. TGF beta expression was found in all patients prior to treatment and while all non-responders showed reduction of TGF beta following treatment, the alterations were variable amongst responders (including two patients with increased expression, one with no change, and one with decreased expression). It is concluded that both IFN and TMX exert multiple effects on the expression of tumour biologic variables and that while the study confirmed some of the predictions from in vitro models, the in vivo effect are more complex than has been appreciated from the models. From the clinical point of view, it might be expected that treatment which enhances the expression of ER in tumours should have a positive effect on the response to TMX. Nature Publishing Group 1993-08 /pmc/articles/PMC1968584/ /pubmed/8347490 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Seymour, L.
Bezwoda, W. R.
Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
title Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
title_full Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
title_fullStr Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
title_full_unstemmed Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
title_short Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
title_sort interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968584/
https://www.ncbi.nlm.nih.gov/pubmed/8347490
work_keys_str_mv AT seymourl interferonplustamoxifentreatmentforadvancedbreastcancerinvivobiologiceffectsoftwogrowthmodulators
AT bezwodawr interferonplustamoxifentreatmentforadvancedbreastcancerinvivobiologiceffectsoftwogrowthmodulators